tbuckley/cabot-search huggingface dataset:
PAPPA-mediated adipose tissue remodeling mitigates insulin resistance and protects against gestational diabetes in mice and humans
Authors: Raziel Rojas-Rodriguez, Rachel Ziegler, Tiffany DeSouza, Sana Majid, Aylin S. Madore, Nili Amir, Veronica A. Pace, Daniel Nachreiner, David Alfego, Jomol Mathew, Katherine Leung, Tiffany A. Moore Simas, Silvia Corvera
Journal: Science Translational Medicine (2020)

A signaling pathway involving the placenta and adipose tissue underlies the development of gestational diabetes.
Text-Book of Medical Jurisprudence and Toxicology.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
73P Selinexor in combination with carboplatin and pemetrexed (CP) in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase Ib study
Authors: K.Z. Thein, A.M. Tsimberidou, S.A. Piha-Paul, F. Janku, D.D. Karp, S. Fu, A. Zarifa, J. Gong, T.A. Yap, D.S. Hong, V. Subbiah, S. Pant, F. Meric-Bernstam, A. Naing
Journal: Annals of Oncology (2020)
Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma
Authors: Juri Kiyokawa, Yoichiro Kawamura, Shanawaz M. Ghouse, Simge Acar, Erinç Barçın, Jordi Martínez-Quintanilla, Robert L. Martuza, Ramon Alemany, Samuel D. Rabkin, Khalid Shah, Hiroaki Wakimoto
Journal: Clinical Cancer Research (2020)

Extracellular matrix (ECM) component hyaluronan (HA) facilitates malignant phenotypes of glioblastoma (GBM), however, whether HA impacts response to GBM immunotherapies is not known. Herein, we investigated whether degradation of HA enhances oncolytic virus immunotherapy for GBM.
Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo
Authors: Silvia Menegatti, Vincent Guillemot, Eleonora Latis, Hanane Yahia-Cherbal, Daniela Mittermüller, Vincent Rouilly, Elena Mascia, Nicolas Rosine, Surya Koturan, Gael A Millot, Claire Leloup, Darragh Duffy, Aude Gleizes, Salima Hacein-Bey-Abina, Jérémie Sellam, Francis Berenbaum, Corinne Miceli-Richard, Maxime Dougados, Elisabetta Bianchi, Lars Rogge
Journal: Annals of the Rheumatic Diseases (2020)

Objectives Antitumour necrosis factor (TNF) therapy has revolutionised treatment of several chronic inflammatory diseases, including spondyloarthritis (SpA). However, TNF inhibitors (TNFi) are not effective in all patients and the biological basis for treatment failure remains unknown. We have analysed induced immune responses to define the mechanism of action of TNF blockers in SpA and to identify immunological correlates of responsiveness to TNFi. Methods Immune responses to microbial and pathway-specific stimuli were analysed in peripheral blood samples from 80 patients with axial SpA before and after TNFi treatment, using highly standardised whole-blood stimulation assays. Cytokines and chemokines were measured in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, and gene expression was monitored using nCounter assays. Results Anti-TNF therapy induced profound changes in patients’ innate immune responses. TNFi action was selective, and had only minor effects on Th1/Th17 immunity. Modular transcriptional repertoire analysis identified prostaglandin E 2 synthesis and signalling, leucocyte recirculation, macrophage polarisation, dectin and interleukin (IL)-1 signalling, as well as the nuclear factor kappa B (NF-kB) transcription factor family as key pathways targeted by TNF blockers in vivo. Analysis of induced immune responses before treatment initiation revealed that expression of molecules associated with leucocyte adhesion and invasion, chemotaxis and IL-1 signalling are correlated with therapeutic responses to anti-TNF. Conclusions We show that TNFi target multiple immune cell pathways that cooperate to resolve inflammation. We propose that immune response profiling provides new insight into the biology of TNF-blocker action in patients and can identify signalling pathways associated with therapeutic responses to biological therapies.
Covid-19: What do we know about the late stage vaccine candidates?
Authors: Elisabeth Mahase
Journal: BMJ (2020)

Covid-19: What do we know about the late stage vaccine candidates?As some phase III trials of covid-19 vaccine candidates report early and unpublished results, Elisabeth Mahase summarises what we know so far Elisabeth Mahase University of Oxford and AstraZeneca vaccineThe ChAdOx1 nCoV-19 has been tested across the world, with trials starting in the UK and branching out to Brazil, South Africa, and the US.Phase II results, published in the Lancet, found that the vaccine produced a similar immune response in old and young participants.Phase III interim results, based on 131 cases, have been made available through a press release (23 November) and suggest the vaccine could be up to 90% effective when a half dose is given, followed by a full dose one month later. 1 When two full doses are given one month apart, however, the effectiveness drops to 62%.Sarah Gilbert-who is leading the vaccine team at the University of Oxford-said the half dose regime may be more effective because it "better mimics" a real infection.They are still, however, investigating this effect.
NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4
Authors: James E Bennett, Vasilis Kontis, Colin D Mathers, Michel Guillot, Jürgen Rehm, Kalipso Chalkidou, Andre P Kengne, Rodrigo M Carrillo-Larco, Ayaga A Bawah, Katie Dain, Cherian Varghese, Leanne M Riley, Ruth Bonita, Margaret E Kruk, Robert Beaglehole, Majid Ezzati
Journal: The Lancet (2020)
16362 Histaminergic angioedema: Burden of illness and impact on quality of life
Authors: Nuria Rodriguez-Garijo, Marina Sabaté Brescó, Julián Azofra, Maria L. Baeza, Pere Gaig, Mar Guilarte, Valeria Herrera-Lasso, Moises Labrador-Horrillo, Beatriz Veleiro, Gil Sanchez, Marta Ferrer
Journal: Journal of the American Academy of Dermatology (2020)
RNA Sequencing Reveals Interacting Key Determinants of Osteoarthritis Acting in Subchondral Bone and Articular Cartilage: Identification of <i>IL11</i> and <i>CHADL</i> as Attractive Treatment Targets
Authors: Margo Tuerlings, Marcella van Hoolwerff, Evelyn Houtman, Eka H. E. D. Suchiman, Nico Lakenberg, Hailiang Mei, Enrike H. M. J. van der Linden, Rob R. G. H. H. Nelissen, Yolande Y. F. M. Ramos, Rodrigo Coutinho de Almeida, Ingrid Meulenbelt
Journal: Arthritis & Rheumatology (2020)

To identify key determinants of the interactive pathophysiologic processes in subchondral bone and cartilage in osteoarthritis (OA).We performed RNA sequencing on macroscopically preserved and lesional OA subchondral bone from patients in the Research Arthritis and Articular Cartilage study who underwent joint replacement surgery due to OA (n = 24 sample pairs: 6 hips and 18 knees). Unsupervised hierarchical clustering and differential expression analyses were conducted. Results were combined with data on previously identified differentially expressed genes in cartilage (partly overlapping samples) as well as data on recently identified OA risk genes.We identified 1,569 genes that were significantly differentially expressed between lesional and preserved subchondral bone, including CNTNAP2 (fold change [FC] 2.4, false discovery rate [FDR] 3.36 × 10-5 ) and STMN2 (FC 9.6, FDR 2.36 × 10-3 ). Among these 1,569 genes, 305 were also differentially expressed, and with the same direction of effect, in cartilage, including the recently recognized OA susceptibility genes IL11 and CHADL. Upon differential expression analysis with stratification for joint site, we identified 509 genes that were exclusively differentially expressed in subchondral bone of the knee, including KLF11 and WNT4. These genes that were differentially expressed exclusively in the knee were enriched for involvement in epigenetic processes, characterized by, e.g., HIST1H3J and HIST1H3H.IL11 and CHADL were among the most consistently differentially expressed genes OA pathophysiology-related genes in both bone and cartilage. As these genes were recently also identified as robust OA risk genes, they classify as attractive therapeutic targets acting on 2 OA-relevant tissues.
A highly effective reverse-transcription loop-mediated isothermal amplification (RT-LAMP) assay for the rapid detection of SARS-CoV-2 infection
Authors: Veronica L. Fowler, Bryony Armson, Jose L. Gonzales, Emma L. Wise, Emma L.A. Howson, Zoe Vincent-Mistiaen, Sarah Fouch, Connor J. Maltby, Seden Grippon, Simon Munro, Lisa Jones, Tom Holmes, Claire Tillyer, Joanne Elwell, Amy Sowood, Oliver de Peyer, Sophie Dixon, Thomas Hatcher, Helen Patrick, Shailen Laxman, Charlotte Walsh, Michael Andreou, Nick Morant, Duncan Clark, Nathan Moore, Rebecca Houghton, Nicholas J. Cortes, Stephen P. Kidd
Journal: Journal of Infection (2020)

The COVID-19 pandemic has illustrated the importance of simple, rapid and accurate diagnostic testing. This study describes the validation of a new rapid SARS-CoV-2 RT-LAMP assay for use on extracted RNA or directly from swab offering an alternative diagnostic pathway that does not rely on traditional reagents that are often in short supply during a pandemic.Analytical specificity (ASp) of this new RT-LAMP assay was 100% and analytical sensitivity (ASe) was between 1 × 101 and 1 × 102 copies per reaction when using a synthetic DNA target. The overall diagnostic sensitivity (DSe) and specificity (DSp) of RNA RT-LAMP was 97% and 99% respectively, relative to the standard of care rRT-PCR. When a CT cut-off of 33 was employed, above which increasingly evidence suggests there is a low risk of patients shedding infectious virus, the diagnostic sensitivity was 100%. The DSe and DSp of Direct RT-LAMP (that does not require RNA extraction) was 67% and 97%, respectively. When setting CT cut-offs of ≤33 and ≤25, the DSe increased to 75% and 100%, respectively, time from swab-to-result, CT < 25, was < 15 min.We propose that RNA RT-LAMP could replace rRT-PCR where there is a need for increased sample throughput and Direct RT-LAMP as a near-patient screening tool to rapidly identify highly contagious individuals within emergency departments and care homes during times of increased disease prevalence ensuring negative results still get laboratory confirmation.
Retrograde esophageal stenting for esophageal stenosis following esophageal atresia repair
Authors: Hsu-Heng Yen, Yao-Jen Hsu, Yu-Wei Fu
Journal: Endoscopy (2020)

A 3-month-old girl was admitted with vomiting following esophageal repair surgery to treat congenital esophageal atresia. Endoscopy revealed stenosis ([Fig. 1]) over the anastomosis site, and she underwent three sessions of endoscopic balloon dilation. During the fourth session of esophageal dilation, dissection of the submucosal layer ([Fig. 2]) occurred after inflation of the balloon, and the procedure was postponed. The patient was subsequently fed via gastrostomy.
Trajectory of Unawareness of Memory Decline in Individuals With Autosomal Dominant Alzheimer Disease
Authors: Patrizia Vannini, Bernard J. Hanseeuw, Jennifer R. Gatchel, Sietske A. M. Sikkes, Diana Alzate, Yesica Zuluaga, Sonia Moreno, Luis Mendez, Ana Baena, Paula Ospina-Lopera, Victoria Tirado, Eliana Henao, Natalia Acosta-Baena, Margarita Giraldo, Francisco Lopera, Yakeel T. Quiroz
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Recent studies have suggested that unawareness, or anosognosia, of memory decline is present in predementia stages of Alzheimer disease (AD) and may serve as an early symptomatic indicator of AD. <h3>Objective</h3> To investigate the evolution of anosognosia of memory decline in individuals who carry the<i>PSEN1</i>E280A variant for autosomal dominant AD compared with family members who do not carry the variant. <h3>Design, Setting, and Participants</h3> This cohort study investigated a total of 2379 members of a Colombian kindred with autosomal dominant AD who were part of the Alzheimer's Prevention Initiative Registry. Assessments were completed at the University of Antioquia, Colombia, with data collected between January 1, 2000, and July 31, 2019. <h3>Main Outcomes and Measures</h3> Awareness of memory function was operationalized using the discrepancy between self-report and study partner report on a memory complaint scale. Linear mixed effects models were used to assess memory self-awareness over age separately in variant carriers and noncarriers. <h3>Results</h3> This study included 396 variant carriers (mean [SD] age, 32.7 [11.9] years; 200 [50.5%] female), of whom 59 (14.9%) were cognitively impaired, and 1983 cognitively unimpaired noncarriers (mean [SD] age, 33.5 [12.5] years; 1129 [56.9%] female). The variant carriers demonstrated increased awareness until the mean (SD) age of 35.0 (2.0) years and had anosognosia at approximately 43 years of age, approximately 6 years before their estimated median age of dementia onset (49 years; 95% CI, 49-51 years). Cognitively unimpaired noncarriers reported more complaints than their study partners aged 20 and 60 years (10.1 points,<i>P</i> &lt; .001). On the awareness index, a decrease with age (mean [SE] estimate, −0.04 [0.02] discrepant-points per years;<i>t</i> = −2.2;<i>P</i> = .03) in the noncarriers and in the variant carriers (mean [SE] estimate, −0.21 [0.04] discrepant-points per years;<i>t</i> = −5.1;<i>P</i> &lt; .001) was observed. <h3>Conclusions and Relevance</h3> In this cohort study, increased participant complaints were observed in both groups, suggesting that increased awareness of memory function was common and nonspecific to AD in this cohort. In variant carriers, awareness of memory function decreased in the predementia stages, reaching anosognosia close to the age of mild cognitive impairment onset, providing support for the usefulness of awareness of memory decline.
Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients With Chronic Hepatitis B
Authors: Pimsiri Sripongpun, W. Ray Kim, Ajitha Mannalithara, Allison Kwong, Tami Daugherty, Aparna Goel, Paul Y. Kwo
Journal: Clinical Gastroenterology and Hepatology (2020)
Abstract AP17: MOLECULAR AND FUNCTIONAL HETEROGENEITY OF CANCER ASSOCIATED FIBROBLASTS IN HIGH-GRADE SEROUS OVARIAN CANCER
Authors: Ali Hussain, Veronique Voisin, Stephanie Poon, Jalna Meens, Julia Dmytryshyn, Josh Paterson, Marcus Bernardini, Gary Bader, Benjamin G Neel, Laurie E Ailles
Journal: Clinical Cancer Research (2019)

Abstract High grade serous ovarian cancer (HGSC) is typically diagnosed at an advanced stage and the vast majority of patients relapse and die within 5 years of diagnosis. Significant clinical problems in HGSC include wide-spread abdominal dissemination of disease and chemotherapy resistance. Cancer-associated fibroblasts (CAFs) have been shown to play a role in promotion of cancer cell proliferation and invasion, and mediation of chemotherapy resistance. To interrogate the molecular properties of CAFs in HGSC we used fluorescence activated cell sorting to isolate CAFs directly from primary tumor samples and performed gene expression profiling. We found that patients stratify into two classes based on their CAF gene signatures: One with high expression of Fibroblast Activation Protein (FAP-High; FH) and one with low expression of FAP (FAP-Low; FL). FH CAFs express classical CAF genes whereas FL CAFs possesses a preadipocyte-like molecular signature. The FL phenotype has remained largely unnoticed as it is generally out-competed in vitro by FH cells when grown under classical CAF culture conditions. Patients from The Cancer Genome Atlas (TCGA), as well as from our own institute, can be stratified into FH and FL subtypes; in both cohorts patients with FH CAFs have a significantly shorter disease-free and overall survival. In vitro and in vivo functional assays performed with isolated CAFs of both types indicate that FH CAFs aggressively promote proliferation, invasion and therapy resistance of cancer cells, whereas FL CAFs do not. Finally, we identified TCF21, a transcriptional repressor, as a FL-specific transcription factor. Analysis of published TCF21 ChIP-Seq data indicates that TCF21 targets a large number of genes specific to FH CAFs. Overexpression of TCF21 in FH CAFs partially reversed their ability to promote cancer cell invasion and tumor growth. Our discovery of CAF heterogeneity in HGSC highlights the need to personalize patient treatment with respect to both cancer and stromal phenotypes. FH patients may benefit from inhibition of cancer-stroma interactions or from epigenetic modulators that reprogram cancer-promoting FH CAFs into the non-supportive FL state. Citation Format: Ali Hussain, Veronique Voisin, Stephanie Poon, Jalna Meens, Julia Dmytryshyn, Josh Paterson, Marcus Bernardini3, Gary Bader, Benjamin G Neel, Laurie E Ailles. MOLECULAR AND FUNCTIONAL HETEROGENEITY OF CANCER ASSOCIATED FIBROBLASTS IN HIGH-GRADE SEROUS OVARIAN CANCER [abstract]. In: Proceedings of the 12th Biennial Ovarian Cancer Research Symposium; Sep 13-15, 2018; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2019;25(22 Suppl):Abstract nr AP17.
Prejudices of a Referenced Philosopher—Reply
Authors: Donald M. Berwick
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Triple Antithrombotic Therapy With Prasugrel in the Stented Patient: Concern for More Bleeding⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Paul A. Gurbel, Udaya S. Tantry
Journal: Journal of the American College of Cardiology (2013)
Abstract 17085: The Penn-Columbia Risks Score Outperforms Other Previously Validated Pre-Operative Risk Scores For Predicting Long-term Outcomes In Lvad Patients
Authors: Ramsey Wehbe, Jane Wilcox, Kambiz Ghafourian, Ike Okwuosa, Faraz S Ahmad, Allen S Anderson, Clyde W Yancy, Duc Pham, Jonathan Rich, Esther Vorovich
Journal: Circulation (2019)

Background: Predicting outcomes after left ventricular assist device (LVAD) implantation is crucial for patient selection. We sought to compare previously validated risk models including the Penn-C...
The case for an HIV cure and how to get there
Authors: Mark Dybul, Timothy Attoye, Solange Baptiste, Peter Cherutich, François Dabis, Steven G Deeks, Carl Dieffenbach, Brian Doehle, Maureen M Goodenow, Adam Jiang, Dominic Kemps, Sharon R Lewin, Murray M Lumpkin, Lauren Mathae, Joseph M McCune, Thumbi Ndung'u, Moses Nsubuga, Holly L Peay, John Pottage, Mitchell Warren, Izukanji Sikazwe
Journal: The Lancet HIV (2020)

In light of the increasing global burden of new HIV infections, growing financial requirements, and shifting funding landscape, the global health community must accelerate the development and delivery of an HIV cure to complement existing prevention modalities. An effective curative intervention could prevent new infections, overcome the limitations of antiretroviral treatment, combat stigma and discrimination, and provide a sustainable financial solution for pandemic control. We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.
<i>Pseudomonas aeruginosa</i> in the Cystic Fibrosis Airway: Does It Deserve Its Reputation as a Predatory “Bully”?
Authors: Dominic A. Hughes, Henry Price, Mark Rosenthal, Jane C. Davies
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

"Pseudomonas aeruginosa in the Cystic Fibrosis Airway: Does It Deserve Its Reputation as a Predatory "Bully"?." American Journal of Respiratory and Critical Care Medicine, 203(8), pp. 1027–1030
13P A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
Authors: J. Chan, Z. Zhang, S-H. Yang, W.S. Ong, V. Tan, T. Rajasekaran, W. Tan, R. Dent, F.Y. Wong, R. Kanesvaran, T.J.Y. Tan
Journal: Annals of Oncology (2020)